No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

1/5

ArborMed

Hyloris

Pharmaceuticals SA

ARBM-101

Copper-binding chelator

Metabolic

disorder

Wilson’s Disease

Preclinical

160

2

1/5

AbbVie

Suzhou Zelgen
Biopharmaceuticals

ZG006

DLL3xDLL3 T-cell engager

Oncology

Solid tumors

Phase 3

1,135

3

1/5

Sanofi

Earendil labs

n/d

AI-driven drug discovery

 platform for BsAbs

Immunology

Autoimmune disease

-

2,560

4

1/6

Pfizer

Cartography

Biosciences

‘Atlas’,
‘Summit’

Platform

Tumor-selective antigen

 discovery platforms

Oncology

Cancer

-

865

5

1/6

Eli Lilly

Nimbus

Therapeutics

-

AI-driven predictive models

Metabolic

disorder

Obesity

-

1,300

6

1/7

Eli Lilly

InduPro

‘Mint’ Platform

AI/ML-enabled membrane

 interactomics platform

Oncology

Immunology

Cancer

Autoimmune disease

n/d

n/d

950

7

1/7

Sidewinder

Therapeutics

Synaffix
(Lonza)

GlycoConnect®,

HydraSpace®,

toxSYN®

Bispecific ADCs

Oncology

Solid tumors

n/d

n/d

8

1/7

Amgen

Disco

Pharmaceuticals

n/d

Cancer Surfaceome Targeted

 Therapies

Oncology

SCLC, CRC

Preclinical

618

9

1/9

J&J

Prazer Therapeutics

‘SPiDEM’

Platform

TPD platform using multiple

 E3 ligases

Neurology

Alzheimer’s disease

n/d

n/d

10

1/9

Madrigal

Pfizer

Ervogastat

DGAT2i inhibitor

Metabolic

disorder

MASH

Phase 2

50

11

1/9

Roche

MediLink

YL201

B7-H3 ADC

Oncology

SCLC,

 Nasopharyngeal carcinoma

Phase 2

570

12

1/12

Abbvie

RemeGen

RC 148

PD-1 x VEGF BsAbs

Oncology

NSCLC, CRC

Phase 2

5,600

13

1/12

Novartis

SciNeuro

Pharmaceuticals

n/d

Amyloid -β targeted antibody

 program

Neurology

Alzheimer’s Disease

Preclinical

165

14

1/13

Eisai

Nuvation Bio

Ibtrozi

;Dovbleron

(Taletrectinib)

ROS1, NTRK1, NTRK2,

 NTRK3 inhibitor

Oncology

ROS1+ NSCLC

Marketed

230

15

1/13

Novartis

Zonsen PepLib
 Biotech

n/d

Peptide-based RLT asset

Oncology

Cancer

n/d

50

16

1/18

AstraZeneca

AbelZeta Pharma

C-CAR031
(AZD7003)

GPC3 CAR-T

Oncology

Hepatocellular carcinoma

Phase 1/2

630

17

1/19

Hygtia

Therapeutics
(Fosun Pharma)

Insilico Medicine

ISM8969

Brain Penetrant NLRP3

 Inhibitor

Neurology

Parkinson’s disease

Preclinical

66

18

1/20

Aspect

Biosystems

Novo Nordisk

-

stem cell-derived islet cell

 and hypoimmune cell

 engineering technologies

Metabolic

disorder

T1D

-

n/d

19

1/20

Pfizer

Novavax

Matrix-M

Induction of T cell–mediated

 immune responses

-

-

-

530

20

1/22

BMS

Janux Therapeutics

n/d

n/d

Oncology

Solid tumors

Preclinical

850

21

1/27

Boehringer

Ingelheim

Simcere

Pharmaceutical

SIM0709

TL1A x IL23p19 BsAbs

Immunology

IBD

Preclinical

1,260

22

1/28

Eli Lilly

Seamless Therapeutics

n/d

Programmable recombinase‑

 based gene editing platform

Neurology

Genetic hearing loss

n/d

1,120

23

1/29

Eli Lilly

Repertoire Immune Medicines

‘DECODE’

Platform

TCR-epitope discovery

 platform

Immunology

Autoimmune Diseases

-

1,925

24

1/30

AstraZeneca

CSPC

Pharmaceuticals

SYH2082

Long-acting GLP1R/GIPR

 agonist

Metabolic

disorder

Obesity, T2D

Phase 1

4,700+

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

1/6

Amgen

Dark Blue
Therapeutics

DBT 3757

TPD; MLLT1/MLLT3 inhibitor

Oncology

AML

Preclinical

840

2

1/7

Eli Lilly

Ventyx Biosciences

VTX2735

VTX3232

VTX002

NLRP3 inhibitor

NLRP3 inhibitor

S1PR1 modulator

Inflammation

Neurology

Immunology

Inflammatory-mediated diseases

Parkinson’s diseases

Ulcerative colitis

Phase 2

Phase 2

Phase 2

1,200

3

1/14

AstraZeneca

Modella AI

-

Generative and agentic AI platform

Oncology

-

-

n/d

4

1/20

GSK

RAPT Therapeutics

Ozureprubart

α-IgE mAb

Inflammation

Food allergy

Phase 2b

2,200

5

1/28

Halozyme Therapeutics

Surf Bio

‘SnapShot’ Platform

Subcutaneous drug-delivery offerings

-

-

-

400